Toll Free: 1-888-928-9744

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 102 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- The report reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics and enlists all their major and minor projects
- The report assesses Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 7 Therapeutics Development 8 Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview 8 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies 9 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies 12 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development 13 Celgene Corporation 13 F. Hoffmann-La Roche Ltd. 14 Gilead Sciences, Inc. 15 Incyte Corporation 16 Italfarmaco S.p.A. 17 JW Pharmaceutical Corporation 18 MEI Pharma, Inc. 19 Nippon Shinyaku Co., Ltd. 20 Novartis AG 21 Pfizer Inc. 22 Promedior, Inc. 23 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 buparlisib hydrochloride - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CWP-291 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 givinostat - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 glasdegib - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 idelalisib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 itacitinib adipate - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 LCL-161 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 momelotinib dihydrochloride - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 NS-018 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 pomalidomide - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 pracinostat - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 PRM-151 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 vismodegib - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Recent Pipeline Updates 68 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects 97 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products 98 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones 99 Featured News & Press Releases 99 Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102
List of Tables
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corporation, H1 2016 13 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 14 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H1 2016 15 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H1 2016 16 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H1 2016 17 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corporation, H1 2016 18 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma, Inc., H1 2016 19 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 20 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2016 21 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc., H1 2016 22 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Recent Pipeline Updates, H1 2016 68 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2016 97 Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2016 98


List of Figures
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Top 10 Targets, H1 2016 25 Number of Products by Stage and Top 10 Targets, H1 2016 25 Number of Products by Top 10 Mechanism of Actions, H1 2016 27 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27 Number of Products by Routes of Administration, H1 2016 29 Number of Products by Stage and Routes of Administration, H1 2016 29 Number of Products by Molecule Types, H1 2016 31 Number of Products by Stage and Molecule Types, H1 2016 31

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify